Duke | MARGOLIS CENTER *for* Health Policy

Reimagining our Shared Approach to Fall Respiratory Virus Seasons:
New Strategies for Transmission Reduction and Population-Level Benefit

November 14, 2023 | 12:30 p.m. – 4:30 p.m. ET
Hybrid Meeting
National Press Club, Washington D.C. & Zoom Webinar

Biographies

Blythe Adamson is an infectious disease epidemiologist and economist. A former member of the White House COVID Task Force on Healthcare Resilience and lead data scientist in the West Wing, she currently serves on the COVID Sports and Society Working Group, advises public and private institutions on safe reopening plans for large-scale in-person gatherings including all major sports leagues, theme parks, retailers, and universities, and is an advisory board member to both NBA-Yale SalivaDirect and Testing for America. Dr. Adamson founded Infectious Economics in 2017 to provide thought leadership to policy makers and industry leaders on cost-effective strategies to prevent the transmission of viruses. Dr. Adamson holds degrees in microbiology, epidemiology, and pharmaceutical economics with a focus on infectious disease prevention. Dr. Adamson has held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling, the HIV Vaccine Trials Network, and Flatiron Health.

Haider Andazola is a senior associate in the firm's Healthcare and Federal Government Strategies groups, specializing in helping healthcare and biotech companies access coverage, coding and payment for their services and technologies under the Medicare and Medicaid programs. His clients span across different healthcare industries and include hospitals, physician practices, payers, pharmacies, pharmaceutical and medical device manufacturers, and digital health technology companies.

David Boucher serves in the immediate office of the Administration for Strategic Preparedness and Response as the Director for Infectious Disease Preparedness and Response, supporting the Assistant Secretary for Preparedness and Response. Dr. Boucher assumed this leadership role following his leadership to Federal efforts to develop, manufacture and procure COVID-19 vaccines and therapeutics and continues to serve in leadership roles for ASPR pandemic preparedness and response efforts, including COVID, mpox, filovirus outbreaks and the infant formula shortage. Dr. Boucher earned degrees in Genetics and Molecular Biology at the University of California, Davis where his research interests spanned hormone-dependent cancers, radiochemistry and nuclear and optical imaging. He joined BARDA during the response to the Ebola outbreak in West Africa and managed the development of FDA-approved therapeutics for Ebola, anthrax and smallpox.

Duke | MARGOLIS CENTER *for* Health Policy

Mandy Cohen is the Director for the Centers for Disease Control and Prevention (CDC) and the Administrator of the Agency for Toxic Substances and Disease Registry. She is one of the nation's top health leaders with experience leading large and complex organizations, and a proven track-record protecting Americans' health and safety. Dr. Cohen is an internal medicine physician and led the North Carolina Department of Health and Human Services, where she was lauded for her outstanding leadership during the COVID crisis, focusing on equity, data accountability, and transparent communication. She also transformed the North Carolina Medicaid program, through the state's Medicaid expansion and her focus on "whole person health" with the launch of the country's first statewide coordination platform, NCCARE360.

Lee Fleisher, former Chief Medical Officer and Director of the Center for Clinical Standards and Quality at the Centers for Medicare & Medicaid Services (CMS), has joined Duke-Margolis as a Visiting Fellow. In this role, Fleisher provides expert perspectives to Duke-Margolis efforts and research on coverage and reimbursement policies, real-world data and evidence, quality measurement and risk adjustment, and more. Currently Emeritus Professor of Anesthesiology and Critical Care and a Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania Perelman School of Medicine, Fleisher teaches the development of novel ideas and technologies to drive quality and value in health care in the Penn Masters in Healthcare Innovation.

Coleen Klasmeier currently serves as Head of Legal—Regulatory Affairs & Patient Safety at Roche Diagnostics. She is a Chambers Band 1-ranked life sciences regulatory lawyer who has represented biopharmaceutical and medical device clients in litigation, transactions, and regulatory matters since 1996. Her professional background includes experiences in two global law firms. She also served as a Staff Attorney and Special Assistant to the Chief Counsel in the Office of the Chief Counsel at the US Food and Drug Administration. Coleen is both the first and the immediate former head of Sidley Austin LLP's top-ranked global Food, Drug and Medical Device Regulatory practice. She was appointed to Sidley's Executive Committee in 2015. Coleen began her career with Covington & Burling where she worked as an associate 2002-04. Coleen has been quoted on FDA matters in the Associated Press, ABC News, Business Week, Bloomberg, Legal Times, The New York Times, Politico, Reuters, The Wall Street Journal, The Washington Post, and US News. Her written work has appeared in the Wall Street Journal (editorial), Health Affairs, the Boston University Law Review, the American Journal of Law & Medicine, the Food & Drug Law Journal (forthcoming), and other trade and lay publications. She has testified on Capitol Hill and is a member of the Washington Legal Foundation's Legal Advisory Board. Coleen is a magna cum laude graduate of the Boston University School of Law, where she was an editor of the law review and received the Melville Madison Bigelow Prize.

Duke | MARGOLIS CENTER *for* Health Policy

Marc Lipsitch is Professor of Epidemiology at the Harvard University T. H. Chan School of Public Health. He directs the Center for Communicable Disease Dynamics and the Interdisciplinary Program on Infectious Disease Epidemiology. He is currently on part-time secondment to the US CDC as Senior Advisor for the newly established Center for Forecasting and Outbreak Analytics (though he speaks in this meeting in his academic/personal capacity). His research concerns the effect of naturally acquired host immunity, vaccine-induced immunity, and other public health interventions on the population biology of pathogens and the consequences for human health. He has authored over 350 peer-reviewed publications on antimicrobial resistance, epidemiologic methods, mathematical modeling of infectious disease transmission, pathogen population genomics, research ethics, and immunoepidemiology of Streptococcus pneumoniae. Dr. Lipsitch is a leader in research and scientific communication on COVID-19. Dr. Lipsitch received his BA in philosophy from Yale and his DPhil in zoology from Oxford. He did postdoctoral work at Emory University and CDC. He is a member of the American Academy of Microbiology and the National Academy of Medicine.

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women's Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development and is an author or co-author of over 100 publications. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Over the past several years he has been integrally involved in the response to various public health emergencies, and in 2022 he was elected a member of the National Academy of Medicine.

Mark McClellan is the Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University. Dr. McClellan is a doctor and an economist who has addressed a wide range of strategies and policy reforms to improve health care, including payment reform to promote better outcomes and lower costs, methods for development and use of real-world evidence, and strategies for more effective biomedical innovation. At the center of the nation's efforts to combat the pandemic, Dr. McClellan is the co-author of a roadmap that details the steps needed for a comprehensive COVID-19 response and safe reopening of our country. Before coming to Duke, he served as a Senior Fellow in Economic Studies at the Brookings Institution, where he was Director of the Health Care Innovation and Value Initiatives and led the Richard Merkin Initiative on Payment Reform and Clinical Leadership. He also has a highly distinguished record in public service and academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy.

Emanuel Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a Distinguished University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program from 2001-2005, and a Senior Investigator within the Center for Biologics Evaluation and Research at the US Food and Drug Administration from 1993-2005. The focus of the CAPMM is the invention and use of proteomics technologies for oncology-based applications, infectious disease research, personalized therapy, molecular diagnostics, and biomarker discovery. He was part of 2 SU2C Dream Teams (pancreatic cancer and melanoma), and is a PI on numerous precision oncology trials including the I-SPY2 TRIAL. He is a co-founder of 3 life science companies including Perthera, Inc., Ceres Nanosciences, Inc. and Theralink Technologies, Inc. Dr. Petricoin's expertise includes host-pathogen interaction dynamics, precision medicine, development of genomics and proteomics-based companion diagnostics, proteomics and protein biomarkers, cell signaling, molecular diagnostic assay development, biologics and cellular therapeutics regulation, as well as artificial intelligence-based algorithms for therapy matching and precision oncology efforts.

Christian Ramers serves as the assistant medical director for research & special populations and director of graduate medical education at Family Health Centers of San Diego. He earned his medical degree from the University of California, San Diego in 2003 and completed his internship and residency at Duke University Medical Center in internal medicine/pediatrics. He completed a fellowship in adult infectious diseases and received a graduate degree in public health at the University of Washington. Dr. Ramers leads several clinical and educational programs supporting HIV and hepatitis C treatment within our clinics, consults for the California Office of AIDS, the CDC and Project ECHO on HIV and HCV-related clinical care initiatives and is a co-investigator on several NIH-sponsored research projects in collaboration with University of California, San Diego and San Diego State University investigators. Dr. Ramers maintains a busy bilingual clinical practice providing specialty and primary care to underserved and homeless individuals of all ages.

Caitlin Rivers is a Senior Scholar at the Johns Hopkins Center for Health Security and an Assistant Professor in the Department of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health. She is an epidemiologist specializing in preparedness and response for epidemics, pandemics, and deliberately occurring events. Dr. Rivers recently returned from an appointment as founding associate director of the Center for Forecasting and Outbreak Analytics at the Centers for Disease Control and Prevention (CDC). Dr. Rivers serves as an Associate Editor of the journal *Health Security* and her writing has been published in the *Washington Post*, *Wall Street Journal*, *New York Times*, and *USA Today*.

Danielle Scelfo is the VP of Market Access and Health Policy at ClearNote Health, and formerly served in similar executive leadership roles at CareDx and Hologic Incorporated. An experienced industry veteran, Ms. Scelfo has chaired the Reimbursement and Policy Workgroup for the Coalition for 21st Century Medicine, co-chaired the Diagnostics Workgroup for the California Healthcare Institute and has been an active member of the two leading US diagnostic trade associations, AdvaMed Dx and the American Clinical Lab Association. Ms. Scelfo has a comprehensive understanding of the US diagnostic industry, Medicare and Medicaid programs, and managed care delivery systems. Her extensive knowledge of government and commercial payer

reimbursement lends valuable insights to the financial impact of reimbursement policy, legislation, and the regulatory rule-making process in healthcare.

Christina Silcox is the Research Director for Digital Health at the Duke-Margolis Center for Health Policy, working on policy solutions to advance innovation in health and health care and improve regulation, reimbursement, and long-term evaluation of medical products, with a focus on digital health. Dr. Silcox's portfolio includes multiple areas in digital health policy and real-world evidence, with an emphasis on medical devices. Currently, she is concentrating on challenges to regulating and adopting of artificial intelligence-enabled software as a medical device, using mHealth to collect real-world data, and characterizing real-world data quality and relevancy. Her projects have included the use of patient-generated health data in medical device evaluations, the exploration of value-based payments for medical devices, and the convening the National Evaluation System for health Technology (NEST) Planning Board.

Sid Tenneti is the Senior Vice President of Retail Pharmacy Growth and Omnichannel. His organization has responsibility for identifying and developing patient interactions that deliver value to the patient and growth for the enterprise. Before CVS Health, Sid worked in a strategy consulting firm focusing on a number of different verticals including pharma. He joined CVS Health in 2009 as part of the Pharmacy Operations team. He has held a number of different roles with increasing responsibility in pharmacy since then including leading Process Innovation, Workforce Management and Rx Personalization. Sid earned a BA in Economics from University of Texas at Austin, a MA in Economics from Northeastern University and an MBA from Babson College.

Brandon Webb is an Associate Professor of Research and Director of Infectious Diseases at Intermountain Health. During the COVID-19 pandemic, Dr. Webb chaired the Intermountain therapeutics committee and directed a monoclonal antibody treatment program. While serving on the emergency response committee for the state of Utah, Dr. Webb led public-private initiatives to increase equity and availability of COVID therapies. He has been an investigator on more than a dozen randomized controlled trials and is the recipient of federal research funding for his work to generate real-world evidence for emerging infectious disease therapeutics.

Anne Zink, as a practicing emergency medicine physician in Alaska, recognized that the emergency department was where all good public health policy comes to fail. She quickly realized that if she was going to care for her patients, she needed to care about health policy as well. She focused her work on the opioid epidemic, complex patient care, workplace violence, and health care reform. Dr. Zink had the honor of becoming the State of Alaska's Chief Medical Officer in July 2019. She and her team led Alaska through the COVID-19 pandemic. She also currently serves as president of ASTHO, the Association of State and Territorial Health Officers. She has special interest in using informatics and information to bring together public health and health care systems to improve the health of the people we all serve and to ensure we all focus on putting the patient first.